New eczema foam shows promise in Late-Stage trial
NCT ID NCT07173478
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a medicated foam called OPA-15406 (difamilast) for adults with atopic dermatitis, a common skin condition causing red, itchy rashes. About 156 participants will apply the foam or a placebo twice daily for 4 weeks. The goal is to see if the foam clears or nearly clears the skin better than the placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPA-15406 (difamilast) foam
- What this could lead to
- If it works, this could offer a new topical foam option to control eczema flare-ups and improve skin clarity.
- What could go wrong
- This is a short 4-week trial with 156 participants, so results may not apply to long-term use or all patients. The foam may not outperform the placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mita Dermatology Clinic
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease